Skip to main content
$8.52 -$0.48 (-5.3%)

02:36 PM EDT on 05/13/21

Trillium Therapeutics Inc (NASDAQ:TRIL)

CAPS Rating: 3 out of 5

Current Price $8.52 Mkt Cap $1.1B
Open $9.13 P/E Ratio 0.00
Prev. Close $10.93 Div. (Yield) $0.00 (0.0%)
Daily Range $8.36 - $9.30 Volume 917,623
52-Wk Range $5.31 - $20.96 Avg. Daily Vol. 1,378,034

Caps

How do you think NASDAQ:TRIL will perform against the market?

Add Stock to CAPS Watchlist

All Players

44 Outperform
3 Underperform
 

All-Star Players

11 Outperform
0 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:TRIL Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.01)
Submitted February 04, 2014

I wish I could come up with something intelligent to say about Stem Cell Therapeutics, but truth is I'm only green thumbing it because I own 35K shares at a cost basis on 0.47 courtesy of Portefeuille. I was up when I made this pick and down as I… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:TRIL VS S&P 500 (SPY)

NASDAQ:TRIL Summary

Fools bearish on NASDAQ:TRIL are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about TRIL.

Recs

0
Member Avatar TMFjbonefish (49.39) Submitted: 11/24/2020 11:44:02 AM : Outperform Start Price: $17.08 NASDAQ:TRIL Score: -64.18

I expect Trillium’s success to continue with positive results at this year’s ASH conference next month. With what management describes as “best in class monotherapy activity”, plenty of cash, and a competitor that was recently acquired for $5 billion, I expect more investors to realize the opportunity for Trillium Therapeutics justifies a market capitalization several times its current size.

Recs

0
Member Avatar JagguShaik (< 20) Submitted: 6/15/2020 12:24:18 AM : Outperform Start Price: $7.42 NASDAQ:TRIL Score: -22.12

Best CD47 inhibitor drug.

Recs

0
Member Avatar odocoileus (56.20) Submitted: 1/29/2020 12:00:28 AM : Outperform Start Price: $2.97 NASDAQ:TRIL Score: +159.32

I've gotten caught up in biotech fads before, some profitable, some not so much. Now the hot new topic is CD47. Real or not, I don't know, but I like the science and it's a new approach. Can you turn off the don't eat me signal and let your body's own immune system kill cancer cells? I made a ton on FTSV (which is not rateable in caps btw). FTSV is a bit ahead of TRIL, but TRIL may have a better product in the end. TRIL still has a small market cap compared to FTSV, but I expect to see a similar run up. If that happens, buckle up, because there is a long way to run.

Leaderboard

Find the members with the highest scoring picks in TRIL.

Score Leader

portefeuille

portefeuille (98.36) Score: +915.29

The Score Leader is the player with the highest score across all their picks in TRIL.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
portefeuille 98.36 4/29/2019 Outperform 5Y $0.70 +1,105.73% +40.17% +1,065.57 0 Comment
portefeuille2 98.81 4/29/2019 Outperform 5Y $0.70 +1,105.73% +40.17% +1,065.57 0 Comment
tilolo76 67.83 1/13/2020 Outperform 5Y $2.86 +194.06% +25.74% +168.32 0 Comment
odocoileus 56.20 1/22/2020 Outperform 5Y $2.97 +183.16% +23.85% +159.32 1 Comment
Paco57 63.28 1/24/2020 Outperform 5Y $3.59 +134.26% +23.80% +110.46 1 Comment
TMFGBudwell 65.95 2/28/2020 Outperform 5Y $3.49 +140.97% +42.67% +98.30 0 Comment
BOBBYLDc 64.24 4/10/2020 Outperform 5Y $4.25 +97.88% +48.21% +49.67 0 Comment
eagles777 72.42 5/4/2020 5/28/2020 Outperform NS $4.30 +95.58% +46.56% +49.03 0 Comment
Under5 68.12 4/27/2020 Outperform 5Y $4.97 +69.22% +44.27% +24.95 0 Comment
gunda7907 46.06 9/12/2017 Outperform 5Y $4.50 +86.89% +64.81% +22.08 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for TRIL.